Lesion-selective Alb-CTLA-4Ig is safe and effective in treating chronic inflammation

Exhibitor: NATIONAL YANG MING CHIAO TUNG UNIVERSITY

Booth No: N327A

Characteristic

CTLA-4Ig has been approved for the treatment of rheumatoid arthritis but may cause systemic immunosuppression. To improve safety, we designed Alb-CTLA-4Ig, a novel recombinant protein linked to albumin that can be cleaved by MMPs. Alb-CTLA-4Ig remains inactive in normal tissues but can be cleaved by MMPs at sites of inflammation. MMP-cleaved Alb-CTLA-4Ig exhibits potent binding and T cell inhibition. In mice with collagen-induced arthritis (CIA), it reduced joint inflammation while preserving antimicrobial immunity. Alb-CTLA-4Ig provides targeted, safer immunosuppression for inflammatory diseases.

Menu

Lesion-selective Alb-CTLA-4Ig is safe and effective in treating chronic inflammation

Characteristic

Other Products

Products you may be interested in

Highest Rated Products